ATM and neoplasm: Regarding the ATRi plus ICB combination, patients with NSCLC treated with ceralasertib and durvalumab in the HUDSON study (Table 1) had a better ORR and PFS when ATM was mutated (ORR of 26.1%, median PFS of 8.4 months) compared to those with ATM-wildtype tumours (ORR of 13% and 6.1% in patients with primary or acquired resistance to ICB, respectively; median PFS of 4.6 months) or acquired resistance to ICB without any biomarker (ORR of 6.1%, median PFS of 4.6 months).